-
1 Comment
tella, Inc is currently in a long term downtrend where the price is trading 41.5% below its 200 day moving average.
From a valuation standpoint, the stock is 0.3% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 70.3.
tella, Inc's total revenue sank by 1.8% to $27M since the same quarter in the previous year.
Its net income has increased by 95.6% to $-10M since the same quarter in the previous year.
Based on the above factors, tella, Inc gets an overall score of 2/5.
Sector | Healthcare |
---|---|
CurrencyCode | JPY |
Industry | Life Sciences Tools & Services |
Exchange | TSE |
ISIN | JP3545900007 |
Beta | 1.85 |
---|---|
Dividend Yield | 0.0% |
Market Cap | 51M |
Target Price | 490 |
PE Ratio | None |
tella, Inc. researches and develops regenerative and cell medicines. The company offers techniques and operational knowhow associated with dendritic cell vaccine therapy to affiliated medical institutions for the treatment of cancer. It is also involved in the provision of consultation services on the establishment and maintenance of cell processing centers, and on introduction of management systems for cell cultivation; and lease of standard operating procedure and regular checks on manufacturing operation management and training of cell cultivation technicians. In addition, the company provides consultation services on training of expertise regarding treatment practice; and support services for the assessment of therapies, documentation required for treatment practice, and cognition and information providing activities for physicians and patients. tella, Inc. was founded in 2004 and is based in Tokyo, Japan.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 2191.TSE using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2024